Lakewood-Amedex Biotherapeutics Announces Completion of Series C Convertible Preferred Stock Redemption
SARASOTA, Fla., Nov. 5, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) (the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class,...